Jubilant Pharmova Ltd

Jubilant Pharmova Ltd

Jubilant Pharmova Ltd's AGM/EGM announcement reports the outcome of a postal ballot, where two special resolutions were passed with the required majority. The resolutions concern the re-appointment of Mr. Priyavrat Bhartia as Managing Director and Mr. Arjun Shanker Bhartia as Joint Managing Director, along with their remuneration. The voting results show a high level of participation, with over 79% of total shares polled in favor of the resolutions.

Jubilant Pharmova Ltd

Jubilant Pharmova Ltd has published unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, in the Financial Express and Hindustan & Jansatta newspapers.

Jubilant Pharmova Ltd

Jubilant Pharmova Ltd has announced its Q1 FY27 results, with revenue growing 17% YoY to Rs. 2,229 Cr, driven by solid growth across all business segments. EBITDA margins declined due to unavailability of high-margin SPECT radiopharmaceutical products and higher operating expenses. The company expects EBITDA margins to expand from H2 FY27 onwards.

Jubilant Pharmova Ltd

Jubilant Pharmova Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, with revenue from operations at Rs. 671 crore and a net profit of Rs. 1 crore.

Jubilant Pharmova Ltd

Jubilant Pharmova Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, with revenue from operations at ₹671 crore and total income at ₹672 crore. The company's board of directors has approved the results, which will be posted on the company's website.

Jubilant Pharmova Ltd

Jubilant Pharmova Ltd has scheduled one-on-one and group meetings with institutional investors from August 13-14, 2026, to discuss Q1 FY27 earnings presentation and financial results.

Jubilant Pharmova Ltd

Jubilant Pharmova Ltd has postponed and rescheduled its Board meeting from August 7, 2026 to August 10, 2026, to consider and approve the Un-audited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026. The trading window for dealing in the company's securities remains closed from July 1, 2026 to August 12, 2026.

Jubilant Pharmova Ltd

Jubilant Pharmova Ltd has published a newspaper advertisement regarding the notice of its 48th Annual General Meeting, e-voting, record date, and final dividend information.

Jubilant Pharmova Ltd

Jubilant Pharmova Ltd has announced a potential deduction of tax at source (TDS) on the final dividend for FY 2025-26, subject to approval by shareholders at the ensuing AGM. The company has also provided details on the procedures to be followed by shareholders for submission of relevant forms and documents.

Jubilant Pharmova Ltd

Jubilant Pharmova Ltd has dispatched letters to shareholders whose email IDs are not registered, providing a weblink to access the Annual Report for FY 2025-26 and Notice of the 48th Annual General Meeting along with TDS Communication.

Jubilant Pharmova Ltd

Jubilant Pharmova Ltd has released its Business Responsibility and Sustainability Report for the financial year 2025-26, as required by SEBI regulations.

Jubilant Pharmova Ltd

Jubilant Pharmova Ltd has announced its 48th Annual General Meeting (AGM) to be held on August 26, 2026, through video conferencing. The meeting will consider the audited financial statements for the year ended March 31, 2026, and re-appointment of directors, including Mr. Arjun Shanker Bhartia and Mr. Hari S. Bhartia. The company also proposes to declare a dividend of ₹5 per equity share.

Jubilant Pharmova Ltd

Jubilant Pharmova Ltd has announced its 48th Annual General Meeting (AGM) to be held on August 26, 2026, through Video Conferencing/Other Audio-Visual Means (VC/OAVM). The AGM notice and annual report for the financial year 2025-26 have been sent to all members whose email addresses are registered with the company/RTA/depository participant(s). The company has provided the facility to vote by electronic means (remote e-voting as well as e-voting at the AGM) to the members who are holding shares on the cut-off date. The remote e-voting will commence at 9:00 a.m. (IST) on Sunday, August 23, 2026, and end at 5:00 p.m. (IST) on Tuesday, August 25, 2026.

Jubilant Pharmova Ltd

Jubilant Pharmova Ltd has announced its 48th Annual General Meeting (AGM) to be held on August 26, 2026, through video conferencing. The company has also released its annual report for the financial year 2025-26 and has proposed a dividend of ₹5 per equity share.

Jubilant Pharmova Ltd

Jubilant Pharmova Ltd has submitted copies of newspaper advertisements relating to notice to shareholders regarding the transfer of equity shares/dividend to the Investor Education and Protection Fund Authority.

Jubilant Pharmova Ltd

Jubilant Pharmova Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2026 to consider and approve the Un-audited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2026.

Jubilant Pharmova Ltd

Jubilant Pharmova Ltd has announced a company update under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, regarding the transfer of unclaimed dividend and equity shares to the Investor Education and Protection Fund (IEPF). The company has sent a communication to shareholders informing them of the transfer and providing details of the unpaid dividend and shares to be transferred. Shareholders are requested to claim the unpaid dividend by making an application to Alankit Assignments Limited before August 31, 2026, to avoid the transfer of shares to the IEPF.

Jubilant Pharmova Ltd

Jubilant Pharmova Ltd announced the 48th Annual General Meeting (AGM) scheduled for August 26, 2026, through video conferencing. The notice and annual report for 2025-26 will be sent to shareholders via email and available on the company's website.